12:42 - 27.07.2026

---

July 27, Fineko/abc.az. AstraZeneca reported an 18% increase in basic earnings in the 2nd quarter up to $2.63 per share, beating analysts' expectations, with revenue of $15.38 billion (+5%). The driver was drugs for oncology and rare diseases, which compensated for the decline in Farxiga revenues in the U.S.

The company has confirmed its 2026 forecasts and revenue target of $80 billion by 2030, expecting further growth in profits and more than 20 key development milestones over the next 18 months.